US2019111049A1PendingUtilityA1

Pain Medicine Combination and Uses Thereof

Assignee: Mindlab LLCPriority: Mar 7, 2013Filed: May 11, 2018Published: Apr 18, 2019
Est. expiryMar 7, 2033(~6.6 yrs left)· nominal 20-yr term from priority
A61P 43/00A61P 25/04A61P 23/00A61K 31/4709A61K 31/49A61K 31/485
46
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Embodiments disclosed herein describe, amongst other things, dosage forms, compounds, compositions, pharmaceutical compositions that can be used in the treatment of, for example, pain and pain related disorders or to produce analgesia.

Claims

exact text as granted — not AI-modified
1 - 51 . (canceled) 
     
     
         52 . A non-sustained release pharmaceutical composition formulated for simultaneous administration consisting essentially of:
 dextromethorphan, or a pharmaceutically acceptable salt thereof;   quinidine, or a pharmaceutically acceptable salt thereof, and   morphine, or a pharmaceutically acceptable salt thereof,   wherein the ratio of morphine, or a pharmaceutically acceptable salt thereof, to dextromethorphan, or a pharmaceutically acceptable salt thereof, to quinidine, or a pharmaceutically acceptable salt thereof, is about 1:1:1 (wt:wt:wt).   
     
     
         53 . The pharmaceutical composition of  claim 52 , wherein the dextromethorphan is dextromethorphan hydrobromide monohydrate. 
     
     
         54 . The pharmaceutical composition of  claim 52 , wherein the quinidine is quinidine gluconate or quinidine sulfate. 
     
     
         55 . The pharmaceutical composition of  claim 52 , wherein the morphine is morphine sulfate. 
     
     
         56 . The pharmaceutical composition of  claim 52 , wherein the composition does not have a sequestered opioid antagonist. 
     
     
         57 . A method of treating pain in a subject in need thereof, the method comprising administering to the subject the pharmaceutical composition of  claim 52 .

Join the waitlist — get patent alerts

Track US2019111049A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.